Daptomycin
A cyclic lipopeptide antibiotic from Streptomyces roseosporus, FDA approved as Cubicin on September 12, 2003 for complicated skin infections and in 2006 for Staphylococcus aureus bacteremia and right-sided endocarditis, now sold as generic intravenous daptomycin.
Also referenced as: LY146032, Cubicin, Cubicin RF, Dapzura RT
Also appears in: Immune
Public product evidence No certificate records are bound to a tracked Daptomycin product page A record counts here only when a vendor publishes a certificate against one of its own tracked Daptomycin product pages. Other certificates naming this compound may still exist — search the wider certificate database.This compound maps to at least one regulated medical product or label context in the United States.
Primary research area: Other. Also surfaces under Immune for browsing and discovery.
Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.
LY146032, Cubicin, Cubicin RF, Dapzura RT
FDA label signal · 140 trials · 1000 PubMed results
Daptomycin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Daptomycin has 52 name-matched clinical trials (1 international) (highest phase: Phase 4) and 1000 PubMed-indexed publications and holds an FDA drug label. 15 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Daptomycin?
Daptomycin is a cyclic lipopeptide antibiotic produced by fermentation of the soil actinomycete Streptomyces roseosporus. It is a 13-residue peptide in which ten amino acids form a ring closed by an ester bond between the C-terminal kynurenine and the hydroxyl of threonine-4, three residues form an exocyclic tail, and a decanoyl fatty acid is attached to the N-terminal tryptophan; ornithine, threo-3-methylglutamate and kynurenine are non-proteinogenic building blocks. The peptide is assembled by a nonribosomal peptide synthetase encoded by the dptA, dptBC and dptD genes (Robbel and Marahiel, Journal of Biological Chemistry, 2010;285(36):27501–27508). The US label gives the empirical formula C72H101N17O26 and a molecular weight of 1,620.67.
Eli Lilly isolated the A21978C lipopeptide complex from S. roseosporus (Debono et al., Journal of Antibiotics, 1987;40(6):761–777) and prepared daptomycin, code LY146032, from it by enzymatic deacylation and chemical reacylation with decanoic acid (Debono et al., Journal of Antibiotics, 1988;41(8):1093–1105). Lilly’s program stalled over skeletal-muscle toxicity, and Cubist Pharmaceuticals licensed the compound and carried it to approval (Eisenstein et al., Clinical Infectious Diseases, 2010;50(Suppl 1):S10–S15). The FDA approved it as Cubicin on September 12, 2003, the first cyclic lipopeptide antibiotic to reach the market, and it is now a standard hospital agent for methicillin-resistant Staphylococcus aureus (MRSA) and other resistant Gram-positive infections. It has no footprint in the research-peptide market.
How it works
- Calcium-dependent membrane insertion and depolarization. In the presence of physiological calcium, daptomycin inserts its decanoyl tail into the Gram-positive cytoplasmic membrane and dissipates the membrane potential. In S. aureus, viability fell by more than 99% and membrane potential by more than 90% within 30 minutes, the two changes tracked each other in time and dose, and calcium-dependent potassium efflux accompanied killing (Silverman et al., Antimicrobial Agents and Chemotherapy, 2003;47(8):2538–2544).
- Disruption of fluid lipid microdomains and cell-wall synthesis. In Bacillus subtilis, daptomycin formed no discrete pores but rearranged fluid lipid domains and rapidly detached the lipid II synthase MurG and the phospholipid synthase PlsX from the membrane, which explains the inhibition of cell-wall synthesis and the gradual depolarization (Müller et al., Proceedings of the National Academy of Sciences, 2016;113(45):E7077–E7086).
- A tripartite complex with cell-wall precursors. Calcium-bound daptomycin binds undecaprenyl-coupled cell-envelope precursors together with phosphatidylglycerol, forming a tripartite complex at the staphylococcal septum that interrupts peptidoglycan synthesis and triggers large membrane rearrangements, which explains the drug’s selectivity for bacterial cells (Grein et al., Nature Communications, 2020;11(1):1455).
- Inactivation by pulmonary surfactant. Daptomycin is active in hematogenous S. aureus pneumonia models but inactive against Streptococcus pneumoniae in bronchoalveolar pneumonia, because it inserts into pulmonary surfactant and loses its antibacterial activity, the first described organ-specific inhibition of an antibiotic (Silverman et al., Journal of Infectious Diseases, 2005;191(12):2149–2152).
Research status
Complicated skin and skin-structure infections (studies 98-01 and 99-01). Two randomized, international phase 3 trials enrolled 1,092 adults with complicated skin and skin-structure infections and compared daptomycin 4 mg/kg once daily with penicillinase-resistant penicillins or vancomycin. Among 902 clinically evaluable patients, clinical success rates were 83.4% with daptomycin and 84.2% with comparators (95% CI for the difference, −4.0 to 5.6), and 63% of successfully treated daptomycin patients needed only 4 to 7 days of intravenous therapy versus 33% of comparator patients (Arbeit et al., Clinical Infectious Diseases, 2004;38(12):1673–1681). These trials supported the original approval of NDA 021572 on September 12, 2003.
S. aureus bacteremia and endocarditis (NCT00093067). An open-label phase 3 trial randomized 246 patients with S. aureus bacteremia, with or without endocarditis, to daptomycin 6 mg/kg daily or to initial low-dose gentamicin plus an antistaphylococcal penicillin or vancomycin. Forty-two days after the end of therapy, success in the modified intention-to-treat analysis was 44.2% (53 of 120) with daptomycin and 41.7% (48 of 115) with standard therapy, a difference of 2.4% (95% CI −10.2 to 15.1) that met the prespecified noninferiority criteria, with similar results in complicated bacteremia, right-sided endocarditis and MRSA subgroups. Microbiologic failure was more frequent with daptomycin (19 versus 11 patients; P = 0.17), with reduced daptomycin susceptibility emerging in 6 of those 19, while clinically significant renal dysfunction was less frequent (11.0% versus 26.3%; P = 0.004) (Fowler et al., New England Journal of Medicine, 2006;355(7):653–665). The trial produced the May 25, 2006 approval of a new indication (supplement 8) for S. aureus bloodstream infections, including right-sided infective endocarditis. Only 18 patients had left-sided endocarditis, with success in 1 of 9 daptomycin patients and 2 of 9 comparator patients, and the label states that daptomycin is not indicated for left-sided S. aureus endocarditis.
Community-acquired pneumonia: two failed phase 3 trials. Two randomized, double-blind trials compared daptomycin 4 mg/kg with ceftriaxone 2 g once daily in adults hospitalized with community-acquired pneumonia. In the pooled intention-to-treat population of 413 daptomycin and 421 ceftriaxone patients, clinical cure was 70.9% versus 77.4% (95% CI for the difference, −12.4 to −0.6%), and in the clinically evaluable population 79.4% versus 87.9% (95% CI −13.8 to −3.2%); cure rates were similar only among patients who had received up to 24 hours of prior effective therapy. The authors concluded that daptomycin is not effective for community-acquired pneumonia (Pertel et al., Clinical Infectious Diseases, 2008;46(8):1142–1151). The surfactant-inactivation mechanism explained the failure, and the US label states that daptomycin is not indicated for the treatment of pneumonia.
Pediatric trials and label extensions. An evaluator-blinded phase 4 trial (NCT00711802) randomized children aged 1 to 17 years with complicated skin infections 2:1 to age-adjusted daptomycin or standard of care (257 versus 132 treated, 35% with confirmed MRSA); treatment-related adverse events were similar (14% versus 17%), and the label reports clinical success of 88% (227 of 257) versus 86% (114 of 132) (Bradley et al., Pediatrics, 2017;139(3):e20162477). A companion trial in S. aureus bacteremia (NCT01728376) randomized 55 children to daptomycin and 27 to standard of care, with drug-related adverse events in 15% of each group and clinical success of 88% versus 77% (95% CI for the difference, −9% to 31%), without a noninferiority design (Arrieta et al., Pediatric Infectious Disease Journal, 2018;37(9):893–900). The FDA added the pediatric skin-infection indication on March 29, 2017 (supplement 55) and the pediatric bacteremia indication on September 1, 2017 (supplement 57).
Comparative evidence and resistance. A systematic review of 20 studies of daptomycin versus vancomycin for MRSA bloodstream infections found a non-significant reduction in mortality odds overall (OR 0.81; 95% CI 0.62 to 1.06), with significant reductions after an early switch to daptomycin and for isolates with vancomycin MICs of 1 mg/L or higher (Adamu et al., PLoS One, 2024;19(2):e0293423). Daptomycin resistance is documented in S. aureus, enterococci and streptococci; its diverse genetic routes converge on adaptive remodeling of cell-wall and membrane homeostasis (Tran et al., Annals of the New York Academy of Sciences, 2015;1354:32–53).
Regulatory history outside the US. The European Medicines Agency issued a marketing authorization for Cubicin (EMEA/H/C/000637) on January 19, 2006, and the product remains authorized in the EU. Japan’s Ministry of Health, Labour and Welfare approved daptomycin in 2011 for MRSA bacteremia, right-sided endocarditis and skin and skin-structure infections (Hagihara et al., Therapeutics and Clinical Risk Management, 2012;8:79–86).
Brand discontinuation and generic transition. Drugs@FDA lists every Cubicin and Cubicin RF presentation under NDA 021572 as discontinued, with a Federal Register determination, published August 7, 2023, that they were not withdrawn for reasons of safety or effectiveness. The first generic vial (ANDA 091039) was approved on March 25, 2016, and as of November 2026 more than a dozen abbreviated applications are marketed, alongside products approved under their own new drug applications: Hikma’s NDA 209949 (October 20, 2017), Hospira’s NDA 210282 (June 21, 2021), Baxter’s NDA 213645 (January 25, 2022) and MAIA Pharmaceuticals’ NDA 217630 (November 21, 2024). As of November 2026, the most recent FDA actions on daptomycin are approvals of additional daptomycin products rather than new indications.
Common dosage forms
- Lyophilized powder vials, 350 mg and 500 mg. The standard US presentation, sold as generic daptomycin for injection by many manufacturers as a single-dose vial of powder for intravenous infusion, prepared and given by hospital pharmacy and nursing staff.
- Premixed daptomycin in 0.9% sodium chloride (Baxter, NDA 213645). Single-dose flexible Galaxy containers of 350 mg/50 mL and 700 mg/100 mL (7 mg/mL) and 500 mg/50 mL and 1,000 mg/100 mL (10 mg/mL) for intravenous infusion.
- Discontinued brand presentations. Cubicin 250 mg and 500 mg vials, Cubicin RF 500 mg vials and Dapzura RT 500 mg vials are listed in Drugs@FDA as discontinued.
- Presentations abroad. Cubicin powder for solution for injection or infusion in the EU, and Cubicin vials for intravenous use in Japan.
Key considerations
- Regulatory status. The FDA Approved status reflects the September 12, 2003 approval of Cubicin (daptomycin) for injection under NDA 021572 for complicated skin and skin-structure infections. The indication was extended on May 25, 2006 to S. aureus bloodstream infections, including right-sided infective endocarditis, and in 2017 to children aged 1 to 17 years. The Cubicin brand presentations have been discontinued, with an FDA determination that they were not withdrawn for safety or effectiveness reasons, and the molecule remains on the US market through generic daptomycin products and daptomycin products approved under their own new drug applications.
- Not a pneumonia drug. Pulmonary surfactant inactivates daptomycin, two phase 3 trials showed inferiority to ceftriaxone in community-acquired pneumonia, and the US label states that the drug is not indicated for pneumonia. Right-sided endocarditis remains within the approved indication, consistent with the drug’s preserved activity in hematogenous S. aureus lung infection models.
- Skeletal-muscle toxicity shaped the regimen. Dog studies showed that muscle effects depended on dosing interval rather than peak concentration or total exposure, with once-daily administration far better tolerated than divided doses (Oleson et al., Antimicrobial Agents and Chemotherapy, 2000;44(11):2948–2953). The US label warns of myopathy and rhabdomyolysis.
- Eosinophilic pneumonia is a labeled signal. An FDA review of adverse-event reports from 2004 to 2010 identified 7 definite, 13 probable and 38 possible cases of daptomycin-associated eosinophilic pneumonia, with onset 10 days to 4 weeks after starting therapy, resolution after withdrawal and recurrence on rechallenge in two definite cases, and the finding was added to the label’s Warnings and Precautions (Kim et al., Drug Safety, 2012;35(6):447–457).
- Naming. LY146032, Cubicin, Cubicin RF and Dapzura RT all denote the same molecule; daptomycin is unrelated to the glycopeptide vancomycin and to the lipoglycopeptides dalbavancin, oritavancin and telavancin.